Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's D&A?
- Avalo Therapeutics (AVTX) reported D&A of $17K in Q2 2026.
- How has Avalo Therapeutics's D&A changed year-over-year?
- Avalo Therapeutics's D&A decreased by 87.3% year-over-year, from $134K to $17K.
- What is the long-term trend for Avalo Therapeutics's D&A?
- Over 4 years (2021 to 2025), Avalo Therapeutics's D&A has grown at a -31.6% compound annual growth rate (CAGR), from $1.58M to $344K.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Avalo Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude